The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials
Fingolimod (1.25 mg) and ozanimod (1 mg) had the best efficacy, and siponimod (1.25 mg and 0.25 mg) had the best safety profile among the S1PRM. Further longitudinal studies should be conducted to assess the long-term effects of these drugs on patient-reported outcomes.
Authors
- Besher Shami (ORCID: https://orcid.org/0009-0002-0685-8991)
- Haroon Shabbir (ORCID: https://orcid.org/0000-0001-8151-2830)
- Syed Ijlal Ahmed (ORCID: https://orcid.org/0000-0003-3896-6380)
- Faizan Shahzad (ORCID: https://orcid.org/0000-0002-8618-1521)
- Haslina Abdul Hamid (ORCID: https://orcid.org/0000-0002-1321-891X)
- Maimoona Siddiqui
- Abdullah Abdullah (ORCID: https://orcid.org/0009-0009-2860-1370)
- Marwah Bintay Khalid
- Taimoon Rasheed
Institutions
- University of Aleppo (SY)
- Rawalpindi Medical University (PK)
- Saint Louis University (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1002/acn3.70122
- Citations
- 2
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.61